Research programme: FGFR4 inhibitors - Tyra Biosciences
Alternative Names: FGFR4 - Tyra Biosciences; FGFR4 programLatest Information Update: 16 Mar 2022
At a glance
- Originator Tyra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Liver cancer; Solid tumours